Information Journal Paper
APA:
CopySIBERIL, S., ROMEUF, C., BIHOREAU, N., FERNANDEZ, N., METERREAU, J.L., & REGENMAN, A.. (2006). SELECTION OF A HUMAN ANTI-RHD MONOCLONAL ANTIBODY FOR THERAPEUTIC USE: IMPACT OF IGG GLYCOSYLATION ON ACTIVATING AND INHIBITORY FC GAMMA R FUNCTIONS. CLINICAL IMMUNOLOGY, 118(-), 170-179. SID. https://sid.ir/paper/564515/en
Vancouver:
CopySIBERIL S., ROMEUF C., BIHOREAU N., FERNANDEZ N., METERREAU J.L., REGENMAN A.. SELECTION OF A HUMAN ANTI-RHD MONOCLONAL ANTIBODY FOR THERAPEUTIC USE: IMPACT OF IGG GLYCOSYLATION ON ACTIVATING AND INHIBITORY FC GAMMA R FUNCTIONS. CLINICAL IMMUNOLOGY[Internet]. 2006;118(-):170-179. Available from: https://sid.ir/paper/564515/en
IEEE:
CopyS. SIBERIL, C. ROMEUF, N. BIHOREAU, N. FERNANDEZ, J.L. METERREAU, and A. REGENMAN, “SELECTION OF A HUMAN ANTI-RHD MONOCLONAL ANTIBODY FOR THERAPEUTIC USE: IMPACT OF IGG GLYCOSYLATION ON ACTIVATING AND INHIBITORY FC GAMMA R FUNCTIONS,” CLINICAL IMMUNOLOGY, vol. 118, no. -, pp. 170–179, 2006, [Online]. Available: https://sid.ir/paper/564515/en